Effects of Fish Oil and Colesevelam (STAIR7007)
Launched by UNIVERSITY OF MANITOBA · Sep 18, 2013
Trial Information
Current as of August 02, 2025
Unknown status
Keywords
ClinConnect Summary
Ezitimibe significantly lowers plant sterol levels in the blood of patients with sitosterolemia. However, plant sterol levels remain substantially elevated compared to those in healthy individuals. Thus, combination therapy needs to be considered. Agents that provide cardiovascular benefits such as colesevelam, a second-generation bile acid sequestrant, and fish oil are potential candidates to help further reduce sterol levels, but have yet to be evaluated in sitosterolemia patients.
The purpose of this study is to dtermine the effects of colesevelam, fish oil and combination therapy (fish...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Confirmed diagnosis of homozygous sitosterolemia as established by genotyping and/or clinical parameters
- • 2. Receiving ezetimibe treatment
- • 3. Over 8 years of age (no maximum)
- • 4. Concomitant illnesses or conditions
- Exclusion Criteria:
- • 1. Pregnancy
- • 2. Intellectual disability
- • 3. Bowel or biliary obstruction
- • 4. Known hypersensitivity to colesevelam or any ingredients of colesevelam
About University Of Manitoba
The University of Manitoba, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive expertise in medical research, public health, and community engagement to conduct rigorous and ethical clinical studies. The institution aims to translate scientific findings into practical applications that enhance patient care and improve health outcomes. Committed to fostering a culture of excellence and integrity, the University of Manitoba prioritizes participant safety and scientific validity in all its clinical research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Winnipeg, Manitoba, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials